These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38735381)

  • 41. Tumor growth suppression by inhibiting both autophagy and STAT3 signaling in HNSCC.
    Fan TF; Bu LL; Wang WM; Ma SR; Liu JF; Deng WW; Mao L; Yu GT; Huang CF; Liu B; Zhang WF; Sun ZJ
    Oncotarget; 2015 Dec; 6(41):43581-93. PubMed ID: 26561201
    [TBL] [Abstract][Full Text] [Related]  

  • 42. STAT3/HOTAIR Signaling Axis Regulates HNSCC Growth in an EZH2-dependent Manner.
    Sun S; Wu Y; Guo W; Yu F; Kong L; Ren Y; Wang Y; Yao X; Jing C; Zhang C; Liu M; Zhang Y; Zhao M; Li Z; Wu C; Qiao Y; Yang J; Wang X; Zhang L; Li M; Zhou X
    Clin Cancer Res; 2018 Jun; 24(11):2665-2677. PubMed ID: 29540490
    [No Abstract]   [Full Text] [Related]  

  • 43. Targeting constitutive and interleukin-6-inducible signal transducers and activators of transcription 3 pathway in head and neck squamous cell carcinoma cells by curcumin (diferuloylmethane).
    Chakravarti N; Myers JN; Aggarwal BB
    Int J Cancer; 2006 Sep; 119(6):1268-75. PubMed ID: 16642480
    [TBL] [Abstract][Full Text] [Related]  

  • 44. TGF-β-induced STAT3 overexpression promotes human head and neck squamous cell carcinoma invasion and metastasis through malat1/miR-30a interactions.
    Wang Y; Wu C; Zhang C; Li Z; Zhu T; Chen J; Ren Y; Wang X; Zhang L; Zhou X
    Cancer Lett; 2018 Nov; 436():52-62. PubMed ID: 30118844
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.
    Gelbert LM; Cai S; Lin X; Sanchez-Martinez C; Del Prado M; Lallena MJ; Torres R; Ajamie RT; Wishart GN; Flack RS; Neubauer BL; Young J; Chan EM; Iversen P; Cronier D; Kreklau E; de Dios A
    Invest New Drugs; 2014 Oct; 32(5):825-37. PubMed ID: 24919854
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Persistent Krüppel-like factor 4 expression predicts progression and poor prognosis of head and neck squamous cell carcinoma.
    Tai SK; Yang MH; Chang SY; Chang YC; Li WY; Tsai TL; Wang YF; Chu PY; Hsieh SL
    Cancer Sci; 2011 Apr; 102(4):895-902. PubMed ID: 21219537
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Potential role of cyclin-dependent kinase 4/6 inhibitors in the treatment of squamous cell carcinoma of the head and neck.
    van Caloen G; Machiels JP
    Curr Opin Oncol; 2019 May; 31(3):122-130. PubMed ID: 30986809
    [TBL] [Abstract][Full Text] [Related]  

  • 48. (-)-Epigallocatechin gallate induces Fas/CD95-mediated apoptosis through inhibiting constitutive and IL-6-induced JAK/STAT3 signaling in head and neck squamous cell carcinoma cells.
    Lin HY; Hou SC; Chen SC; Kao MC; Yu CC; Funayama S; Ho CT; Way TD
    J Agric Food Chem; 2012 Mar; 60(10):2480-9. PubMed ID: 22313388
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
    Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
    Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma.
    Qie S; Yoshida A; Parnham S; Oleinik N; Beeson GC; Beeson CC; Ogretmen B; Bass AJ; Wong KK; Rustgi AK; Diehl JA
    Nat Commun; 2019 Mar; 10(1):1296. PubMed ID: 30899002
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fibroblast growth factor receptor 3-mediated reactivation of ERK signaling promotes head and neck squamous cancer cell insensitivity to MEK inhibition.
    Ban MJ; Byeon HK; Yang YJ; An S; Kim JW; Kim JH; Kim DH; Yang J; Kee H; Koh YW
    Cancer Sci; 2018 Dec; 109(12):3816-3825. PubMed ID: 30343534
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck.
    Boehm AL; Sen M; Seethala R; Gooding WE; Freilino M; Wong SM; Wang S; Johnson DE; Grandis JR
    Mol Pharmacol; 2008 Jun; 73(6):1632-42. PubMed ID: 18326051
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The interaction of interleukin-8 and PTEN inactivation promotes the malignant progression of head and neck squamous cell carcinoma via the STAT3 pathway.
    Xu Q; Ma H; Chang H; Feng Z; Zhang C; Yang X
    Cell Death Dis; 2020 May; 11(5):405. PubMed ID: 32471980
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
    Seiwert TY; Jagadeeswaran R; Faoro L; Janamanchi V; Nallasura V; El Dinali M; Yala S; Kanteti R; Cohen EE; Lingen MW; Martin L; Krishnaswamy S; Klein-Szanto A; Christensen JG; Vokes EE; Salgia R
    Cancer Res; 2009 Apr; 69(7):3021-31. PubMed ID: 19318576
    [TBL] [Abstract][Full Text] [Related]  

  • 55. TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma.
    Ruicci KM; Meens J; Plantinga P; Stecho W; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Boutros PC; Ailles L; Nichols AC
    J Exp Clin Cancer Res; 2020 Oct; 39(1):217. PubMed ID: 33059733
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Do CDK4/6 inhibitors have potential as targeted therapeutics for squamous cell cancers?
    Kalu NN; Johnson FM
    Expert Opin Investig Drugs; 2017 Feb; 26(2):207-217. PubMed ID: 28042706
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Acetyl-CoA carboxylase rewires cancer metabolism to allow cancer cells to survive inhibition of the Warburg effect by cetuximab.
    Luo J; Hong Y; Lu Y; Qiu S; Chaganty BK; Zhang L; Wang X; Li Q; Fan Z
    Cancer Lett; 2017 Jan; 384():39-49. PubMed ID: 27693630
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular mechanisms of anti-tumor properties of P276-00 in head and neck squamous cell carcinoma.
    Mishra PB; Lobo AS; Joshi KS; Rathos MJ; Kumar GA; Padigaru M
    J Transl Med; 2013 Feb; 11():42. PubMed ID: 23414419
    [TBL] [Abstract][Full Text] [Related]  

  • 59. AKR1C1 controls cisplatin-resistance in head and neck squamous cell carcinoma through cross-talk with the STAT1/3 signaling pathway.
    Chang WM; Chang YC; Yang YC; Lin SK; Chang PM; Hsiao M
    J Exp Clin Cancer Res; 2019 Jun; 38(1):245. PubMed ID: 31182137
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells.
    Cao Y; Li X; Kong S; Shang S; Qi Y
    J Cell Mol Med; 2020 May; 24(9):5135-5145. PubMed ID: 32277580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.